Yahoo Finance • 2 months ago
Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC) NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) ("AbbVie") and Landos Bio... Full story
Yahoo Finance • 6 months ago
NX-13, a Novel, Oral, NLRX1 Agonist, was Observed to be Well Tolerated and Demonstrated Early Signs of Rapid Symptomatic Relief and Endoscopic Improvement in Patients with Ulcerative Colitis NEXUS Phase 2 Proof-of-Concept Study is Ongoing... Full story
Yahoo Finance • 6 months ago
NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Remains On Track with Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Land... Full story
Yahoo Finance • 7 months ago
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will present ad... Full story
Yahoo Finance • 8 months ago
NX-13 Demonstrated Rapid Symptomatic Relief and Improvement in Multiple Biomarkers that Correlated With Early Endoscopic Response in Patients With Ulcerative Colitis (UC) NEXUS Phase 2 Clinical Trial is Ongoing; Top-line Readout Expected... Full story
Yahoo Finance • 8 months ago
NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a strategic research c... Full story
Yahoo Finance • a year ago
NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) -- Landos Bio... Full story
Yahoo Finance • a year ago
NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) -- Landos Bio... Full story
Yahoo Finance • a year ago
On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the Second Quarter of 2023 and Report Topline Results by the Fourth Quarter of 2024 Projected Cash Runway into First Half of 2025 NEW YORK, March 23,... Full story
Yahoo Finance • a year ago
Transaction Solidifies Company’s Near-Term Strategic Focus on Advancing Clinical Development of NX-13 Company Remains On-Track to Initiate the NX-13 Phase 2 Proof-of-Concept Trial in Ulcerative Colitis in the Second Quarter of 2023 NEW Y... Full story
Yahoo Finance • a year ago
NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today annou... Full story
Yahoo Finance • a year ago
Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis On Track to Initiate Phase 2 Proof-of-Concept Trial for NX-13 in the Second Quarter of 2023 and Report Topline Data by the Fourth Quarter of 2024 Broader, Novel Pip... Full story
Yahoo Finance • a year ago
NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today annou... Full story
Yahoo Finance • 2 years ago
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced financial results for t... Full story
Yahoo Finance • 2 years ago
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Fab... Full story
Yahoo Finance • 2 years ago
Positive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety and Tolerability Profile Across Range of Once-Daily Oral Doses, as well as Promising Early Efficacy Signals Phase 2 Proof of Concept... Full story
Yahoo Finance • 2 years ago
NX-13 Demonstrated Favorable Safety and Tolerability Profile Across Range of Once-Daily Doses Results Indicate Promising Early Signals Regarding the Efficacy of NX-13 Phase 2 Proof of Concept Clinical Trial in Ulcerative Colitis Planned... Full story
Yahoo Finance • 2 years ago
Seasoned Pharmaceutical Executive Brings 25+ Years of Experience With a Focus on Successful Commercialization Company Remains On Track to Complete Review of Clinical Development Plans Later This Year NEW YORK, June 21, 2022 (GLOBE NEWS... Full story